该产品被引用文献
1, Dwyer, C; et al. Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients. iScience
2, Boonyaratanakornkit, J; et al. Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43. Viruses, Pubmed: 34696505
3, Li, M; et al. Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19 convalescent individuals. The Journal of allergy and clinical immunology, Pubmed: 35074422
4, Li, CJ; et al. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion. Microbiology spectrum, Pubmed: 35293796
5, Lai, GC; et al. Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain. Antiviral research, Pubmed: 35296418
6, Sun, X; et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nature microbiology, Pubmed: 35773398
7, Zhao, M; et al. La catepsina L desempeña un papel clave en la infección por SARS-CoV-2 en humanos y ratones humanizados y es un objetivo prometedor para el desarrollo de nuevos fármacos. Transducción de señales y terapia dirigida
8, Steiner, D; et al. Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients. bioRxiv
9, Zhou, D; et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. bioRxiv
10, Kim, SY; et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res., Pubmed: 32653452